Table 2.
Lipid-related parameters of placebo and test group at baseline and 12-week follow up
| Placebo group (n = 38) | uRC group (n = 39) | Pa | Pb | Pc | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Follow-up | Baseline | Follow-up | ||||||||
| Total-cholesterol (mg/dL) | 213.86 | ±1.79 | 208.81 | ±3.95 | 214.05 | ±1.50 | 192.82 | ±4.07 | 0.938 | 0.006 | |
| Change | −5.05 | ±3.84 | −21.23 | ±4.36 | 0.007 | ||||||
| Triglyceride (mg/dL) | 111.45 | ±6.22 | 119.26 | ±7.70 | 116.05 | ±7.13 | 115.49 | ±8.13 | 0.629 | 0.737 | |
| Change | −7.82 | ±7.84 | --0.56 | ±7.06 | 0.429 | ||||||
| LDL-cholesterol (mg/dL) | 135.60 | ±2.58 | 132.55 | ±4.26 | 133.41 | ±2.06 | 117.79 | ±4.34 | 0.508 | 0.018 | |
| Change | −3.05 | ±3.95 | −15.61 | ±4.16 | 0.032 | ||||||
| Non-HDL-cholesterol (mg/dL) | 153.71 | ±3.13 | 147.03 | ±4.33 | 153.41 | ±2.63 | 133.28 | ±4.40 | 0.942 | 0.029 | |
| Change | −6.68 | ±3.30 | −20.13 | ±4.14 | 0.013 | ||||||
| Apolipoprotein B (mg/dL) | 114.39 | ±2.75 | 120.60 | ±3.82 | 115.17 | ±2.83 | 111.69 | ±3.46 | 0.843 | 0.088 | |
| Change | 6.21 | ±2.84 | −3.48 | ±3.40 | 0.032 | ||||||
| Oxidized LDL (U/L) | 68.05 | ±3.02 | 66.09 | ±3.47 | 64.31 | ±2.53 | 57.76 | ±2.07 | 0.348 | 0.044 | |
| Change | −1.95 | ±2.41 | −6.23 | ±1.96 | 0.174 | ||||||
Mean ± SE (Standard Error), Pa-values derived from independent t-test at baseline baseline between the placebo and the uRC group. Pb-values derived from independent t-test at 12-week follow up between the placebo and the uRC group. Pc-values derived from independent t-test for changed value between the placebo and the uRC group. Change value (Δ, delta) represents the change from baseline at follow-up